Edythe M. Greenberg, PhD, RN, FNP-BCDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Nursing Experience in Patients with Chronic Lymphocytic Leukemia Receiving First-Line Ibrutinib: Five Years of Follow-Up from the Phase 3 RESONATE-2 Study
Jillian Settlemire, RN, Edythe M. Greenberg, PhD, RN, FNP-BC, Indu Lal, MD, Carlos Amaya-Chanaga, MD, Jan A. Burger, MD, PhD, Steven Coutre, MD
November 13, 2020 | November 2020 Vol 11, No 11
Ibrutinib is the only once-daily Bruton tyrosine kinase inhibitor that has shown significant progression-free survival (PFS) and overall survival (OS) benefits in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) across multiple randomized phase 3 studies.
Four Years of Follow-Up for Ibrutinib as First-Line Treatment of Older Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Long-Term Data and Oncology Nurses’ Experience with Adverse Event Management
Edythe M. Greenberg, PhD, RN, FNP-BC, Jillian Settlemire, RN, Sandra Dai, PhD, MS, James P. Dean, MD, PhD, Tony Lin, PharmD, Steven Coutre, MD, Jan Berger, MD, PhD
November 9, 2018 | November 2018 Vol 9, NO 11
Ibrutinib is a first-in-class, once-daily inhibitor of BTK approved in the United States for treatment of CLL/SLL. RESONATE-2 is a phase 3 study comparing first-line ibrutinib versus chlorambucil in patients with CLL/SLL. Primary results (median follow-up, 18.4 months) demonstrated ibrutinib reduced risk of progressive disease (PD) or death by 84% (Burger, 2015).
Last modified: November 13, 2020